OncoMed: AACR-NCI-EORTC 2015 (OncoMed) - Dec 10, 2015 - “BRON was generally well tolerated”; “The recommended single-agent phase 2 dose is 1.5 mg/kg Q3W”; “The main toxicity of BRON is on-target diarrhea. Other less common events included fatigue, nausea, and vomiting: Diarrhea is a known on-target effect of Notch inhibition and was controlled in most cases”; “BRON has shown single-agent efficacy, where several pts had stable disease and two patients had a partial response, particularly in the biomarker-defined population (NICD high): Activity observed in ACC, CRC, and breast cancer”; “The dose cohorts at or above 1.5 mg/kg Q3W showed clear target engagement in blood and the tumor”
P1 data • Oncology
|